Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04788472

Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL

B-Cell Acute Lymphoblastic Leukemia, Adult Clinical Trial

Official title:
Clinical Trial for the Safety and Efficacy of Sequential CD19 and CD22 CAR-T Therapy for Adult Patients With Newly Diagnosed Ph Chromosome Positive B-cell Acute Lymphoblastic Leukemia

Clinical Trial Summary

Clinical Trial for the Safety and Efficacy of Sequential CD19 and CD22 CAR-T Therapy for Adult Patients With Newly Diagnosed Ph Chromosome Positive B-cell Acute Lymphoblastic Leukemia

Clinical Trial Description

This is a prospective, single arm study. To evaluate the safety and efficacy of sequential CD19 and CD22 CAR-T cells in the treatment of adult newly diagnosed Ph chromosome positive B-cell acute lymphoblastic leukemia. The main endpoints were dose limiting toxicity (DLT) and incidence of adverse events (TEAEs). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04788472
Study type Interventional
Source Zhejiang University
Contact He Huang, PhD
Phone 86-13605714822
Email hehuangyu@126.com
Status Recruiting
Phase Phase 1/Phase 2
Start date March 5, 2021
Completion date March 5, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04740203 - Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL Phase 1/Phase 2
Active, not recruiting NCT04214886 - CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies Phase 1
Active, not recruiting NCT03160079 - Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts Phase 1/Phase 2